NEW YORK – A team led by researchers at the University of Oxford has used genetics to show that treating patients with an anti-osteoporotic drug called romosozumab might increase their risk of cardiovascular complications.
NEW YORK – A team led by researchers at the University of Oxford has used genetics to show that treating patients with an anti-osteoporotic drug called romosozumab might increase their risk of cardiovascular complications.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.